Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-001 SAD and MAD Study in Healthy Adults
NCT07876076Phase 1Recruiting
- Sponsor
- Adaxion Therapeutics, Inc.
- Start
- Oct 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DSPE-DOTA-Gd in inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease and 1 more (2 cohorts), sponsored by Adaxion Therapeutics, Inc. Primary endpoint: Incidence and severity of Treatment Emergent Adverse Events at Day 505. Started Oct 2026; status: recruiting.
02
Drugs
DSPE-DOTA-Gd
03
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)Crohn's diseasepsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07876076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876076.